Key result
DOACs provide effective venous thromboembolism treatment without routine laboratory monitoring.
Why the study?
Anticoagulant treatment for VTE has evolved with new oral anticoagulants undergoing extensive clinical evaluation, necessitating an updated overview of management advances.
New oral anticoagulants offer a promising alternative to traditional therapies for VTE management, as they do not require laboratory monitoring and are administered at fixed doses.
May support NOAC consideration for VTE without monitoring; leaves open need for prospective validation.
Venous thromboembolism (VTE) is a spectrum of diseases that includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Anticoagulant treatment is the mainstay of therapy for VTE. Unfractionated heparin (UFH) or low molecular weight heparin (LMWH) followed by vitamin K antagonists have been the treatment of choice for most patients with VTE, with the aim to prevent thrombus extension or embolization and recurrent VTE. Fondaparinux, a selective, indirect, parenteral factor Xa inhibitor, is now also approved for the initial treatment of VTE and represents an important alternative to UFH or LMWH. Secondary prevention of VTE with vitamin K antagonists is usually prescribed for a minimum of three months, with the duration of treatment based on the presence or absence of major identifiable risk factors for the index event. Patients with permanent risk factors or patients with recurrent DVT or PE require life long secondary prevention. Over the last years, new oral anticoagulant agents have been developed and are now undergoing extensive clinical evaluation in several settings, including the treatment of VTE. New oral anticoagulants include selective, direct thrombin inhibitors, such as dabigatran etexilate, and selective, direct factor Xa inhibitos, such as rivaroxaban, apixaban or edoxaban. All these drugs are admistered at fixed daily doses and do not require laboratory monitoring. The positive results of the first completed clinical trials suggest that a new era in the management of VTE is about to begin.
No takes yet. Share an insight, caveat, or question.
Walter Ageno (2010) conducted a review in Venous thromboembolism. New oral anticoagulants (direct thrombin and factor Xa inhibitors) vs. Standard therapy (heparins and vitamin K antagonists) was evaluated. New oral anticoagulants, including direct thrombin inhibitors and direct factor Xa inhibitors, offer effective treatment for venous thromboembolism without requiring routine laboratory monitoring.